Comparative Pharmacology
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE versus BUPIVACAINE HYDROCHLORIDE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE versus BUPIVACAINE HYDROCHLORIDE KIT.
ARESTOCAINE HYDROCHLORIDE vs BUPIVACAINE HYDROCHLORIDE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Bupivacaine is an amide-type local anesthetic that blocks sodium channels in neuronal cell membranes, inhibiting the propagation of action potentials and thus producing local anesthesia and analgesia.
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
0.25% to 0.5% solution administered via epidural, peripheral nerve block, or local infiltration; maximum single dose 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000); may repeat every 3-6 hours as needed, not to exceed 400 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Terminal elimination half-life is 2.7 to 3.5 hours in adults, prolonged in neonates (8-14 hours) and patients with hepatic impairment. Clinically, this supports intermittent dosing or continuous infusion monitoring.
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Primarily hepatic metabolism (approx. 95%) to metabolites (e.g., pipecoloxylidine, desbutylbupivacaine); less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for a minor fraction. Renal clearance of unchanged drug is about 2-6%.
Category C
Category C
Local Anesthetic
Local Anesthetic